ES2910110T3 - Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A - Google Patents
Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A Download PDFInfo
- Publication number
- ES2910110T3 ES2910110T3 ES17816630T ES17816630T ES2910110T3 ES 2910110 T3 ES2910110 T3 ES 2910110T3 ES 17816630 T ES17816630 T ES 17816630T ES 17816630 T ES17816630 T ES 17816630T ES 2910110 T3 ES2910110 T3 ES 2910110T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- methoxy
- isoxazol
- carboxamide
- methylpyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202889 | 2016-12-08 | ||
| PCT/EP2017/081768 WO2018104419A1 (fr) | 2016-12-08 | 2017-12-07 | Nouveaux dérivés d'éther isoxazolyle en tant que gaba a alpha5 pam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2910110T3 true ES2910110T3 (es) | 2022-05-11 |
Family
ID=57530563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17816630T Active ES2910110T3 (es) | 2016-12-08 | 2017-12-07 | Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11091471B2 (fr) |
| EP (1) | EP3551627B1 (fr) |
| JP (1) | JP7084405B2 (fr) |
| KR (1) | KR102564643B1 (fr) |
| CN (2) | CN109923113B (fr) |
| AR (1) | AR110498A1 (fr) |
| AU (1) | AU2017373734B2 (fr) |
| BR (1) | BR112019006571A2 (fr) |
| CA (1) | CA3040024A1 (fr) |
| CL (1) | CL2019001458A1 (fr) |
| CO (1) | CO2019002692A2 (fr) |
| CR (1) | CR20190268A (fr) |
| DK (1) | DK3551627T3 (fr) |
| ES (1) | ES2910110T3 (fr) |
| HR (1) | HRP20220468T1 (fr) |
| HU (1) | HUE058355T2 (fr) |
| IL (1) | IL267054B (fr) |
| LT (1) | LT3551627T (fr) |
| MA (1) | MA48594B1 (fr) |
| MX (1) | MX388725B (fr) |
| MY (1) | MY200641A (fr) |
| PE (1) | PE20191156A1 (fr) |
| PH (1) | PH12019500664B1 (fr) |
| PL (1) | PL3551627T3 (fr) |
| PT (1) | PT3551627T (fr) |
| RS (1) | RS63106B1 (fr) |
| SI (1) | SI3551627T1 (fr) |
| TW (1) | TWI642666B (fr) |
| UA (1) | UA125524C2 (fr) |
| WO (1) | WO2018104419A1 (fr) |
| ZA (1) | ZA201902225B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190268A (es) | 2016-12-08 | 2019-07-11 | Hoffmann La Roche | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 |
| IL279266B2 (en) | 2018-06-13 | 2024-03-01 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| WO2021191837A1 (fr) * | 2020-03-26 | 2021-09-30 | Richter Gedeon Nyrt. | Dérivés de 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine utilisés en tant que modulateurs du récepteur gabaa α5 |
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| KR20240005848A (ko) | 2021-05-05 | 2024-01-12 | 유니버시티 칼리지 카디프 컨설턴츠 리미티드 | 인지 장애의 치료에 유용한 헤테로아릴 화합물 |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| AU2023288711A1 (en) | 2022-06-20 | 2024-11-07 | F. Hoffmann-La Roche Ag | Crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4- yl)methoxy)-n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide |
| AU2023370005A1 (en) | 2022-10-25 | 2025-04-10 | F. Hoffmann-La Roche Ag | Process for manufacturing alogabat |
| CN121001709A (zh) | 2023-04-24 | 2025-11-21 | 豪夫迈·罗氏有限公司 | 包含6-((5-甲基-3-(6-甲基吡啶-3-基)异噁唑-4-基)甲氧基)-n-(四氢吡喃-4-基)哒嗪-3-甲酰胺的片剂 |
| CN119080754A (zh) * | 2023-06-05 | 2024-12-06 | 武汉人福创新药物研发中心有限公司 | 作为α5-GABAA受体调节剂的杂环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100015648A (ko) | 2007-04-18 | 2010-02-12 | 아스트라제네카 아베 | 양성 알로스테릭 ｇａｂａｂ 수용체 조절제 효과를 갖는 크산틴 화합물 |
| JP5301557B2 (ja) * | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| SG175867A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-pyridine derivatives |
| PH12013500676A1 (en) | 2010-11-05 | 2013-05-06 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| JP6012735B2 (ja) * | 2011-09-15 | 2016-10-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ジヒドロキノリン−２−オン誘導体 |
| MA42659A (fr) | 2015-08-17 | 2018-06-27 | Lupin Ltd | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp |
| CA3151595A1 (fr) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulateurs de l'ecto-5'-nucleotidase et leur utilisation |
| BR112018013761A2 (pt) | 2016-01-08 | 2018-12-11 | Celgene Corp | compostos antiproliferativos e suas composições farmacêuticas e usos |
| CR20190268A (es) | 2016-12-08 | 2019-07-11 | Hoffmann La Roche | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 |
-
2017
- 2017-12-07 CR CR20190268A patent/CR20190268A/es unknown
- 2017-12-07 AR ARP170103429A patent/AR110498A1/es active IP Right Grant
- 2017-12-07 WO PCT/EP2017/081768 patent/WO2018104419A1/fr not_active Ceased
- 2017-12-07 MY MYPI2019001529A patent/MY200641A/en unknown
- 2017-12-07 PL PL17816630T patent/PL3551627T3/pl unknown
- 2017-12-07 BR BR112019006571-7A patent/BR112019006571A2/pt active Search and Examination
- 2017-12-07 CN CN201780069758.2A patent/CN109923113B/zh active Active
- 2017-12-07 KR KR1020197016011A patent/KR102564643B1/ko active Active
- 2017-12-07 ES ES17816630T patent/ES2910110T3/es active Active
- 2017-12-07 MA MA48594A patent/MA48594B1/fr unknown
- 2017-12-07 EP EP17816630.2A patent/EP3551627B1/fr active Active
- 2017-12-07 DK DK17816630.2T patent/DK3551627T3/da active
- 2017-12-07 SI SI201731124T patent/SI3551627T1/sl unknown
- 2017-12-07 MX MX2019006696A patent/MX388725B/es unknown
- 2017-12-07 LT LTEPPCT/EP2017/081768T patent/LT3551627T/lt unknown
- 2017-12-07 PE PE2019001006A patent/PE20191156A1/es unknown
- 2017-12-07 JP JP2019530755A patent/JP7084405B2/ja active Active
- 2017-12-07 PH PH1/2019/500664A patent/PH12019500664B1/en unknown
- 2017-12-07 RS RS20220321A patent/RS63106B1/sr unknown
- 2017-12-07 HR HRP20220468TT patent/HRP20220468T1/hr unknown
- 2017-12-07 PT PT178166302T patent/PT3551627T/pt unknown
- 2017-12-07 TW TW106142872A patent/TWI642666B/zh active
- 2017-12-07 CA CA3040024A patent/CA3040024A1/fr active Pending
- 2017-12-07 UA UAA201907047A patent/UA125524C2/uk unknown
- 2017-12-07 HU HUE17816630A patent/HUE058355T2/hu unknown
- 2017-12-07 AU AU2017373734A patent/AU2017373734B2/en active Active
- 2017-12-07 CN CN202311216893.9A patent/CN117285525A/zh active Pending
-
2019
- 2019-03-26 CO CONC2019/0002692A patent/CO2019002692A2/es unknown
- 2019-04-09 ZA ZA2019/02225A patent/ZA201902225B/en unknown
- 2019-05-29 CL CL2019001458A patent/CL2019001458A1/es unknown
- 2019-06-03 IL IL267054A patent/IL267054B/en unknown
- 2019-06-05 US US16/432,584 patent/US11091471B2/en active Active
-
2021
- 2021-07-16 US US17/378,410 patent/US20220411415A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,606 patent/US20240279218A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2910110T3 (es) | Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A | |
| US11739095B2 (en) | Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators | |
| US11840528B2 (en) | Isoxazolyl ether derivatives as GABAA α5 PAM | |
| US20240270744A1 (en) | New pyrido diazepine derivatives as gaba a gamma1 pam | |
| RU2772862C2 (ru) | Новые эфирные производные изоксазола в качестве позитивных аллостерических модуляторов рецептора гамк а альфа 5 | |
| JP7739336B2 (ja) | Ｇａｂａ ａ ａｌｐｈａ５ ｐａｍとしての新規トリアゾリル誘導体 | |
| NZ794798A (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| HK40096511A (zh) | 作为GABA A α5 PAM的新型异恶唑基醚衍生物 | |
| RU2800160C2 (ru) | Новые производные простого эфира изоксазолила в качестве пам гамк a альфа5 | |
| US20240190889A1 (en) | New cyclopenta-thieno-diazepine derivatives as gaba a gamma1 positive allosteric modulators | |
| HK40005975B (zh) | 作为GABA A α5 PAM的异恶唑基醚衍生物 | |
| HK40005975A (en) | Isoxazolyl ether derivatives as gaba a alpha5 pam |